home / stock / mbrx / mbrx quote
Last: | $4.63 |
---|---|
Change Percent: | -4.45% |
Open: | $4.5 |
Close: | $4.63 |
High: | $4.8966 |
Low: | $4.405 |
Volume: | 23,885 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$4.63 | $4.5 | $4.63 | $4.8966 | $4.405 | 23,885 | 04-26-2024 |
$4.3082 | $4.3 | $4.3082 | $4.4999 | $4.28 | 22,596 | 04-25-2024 |
$4.35 | $4.46 | $4.35 | $4.622 | $4.35 | 7,365 | 04-24-2024 |
$4.6 | $4.29 | $4.6 | $4.6 | $4.29 | 7,385 | 04-23-2024 |
$4.3 | $4.78 | $4.3 | $4.78 | $4.3 | 16,771 | 04-22-2024 |
$4.65 | $4.59 | $4.65 | $4.66 | $4.4001 | 10,562 | 04-19-2024 |
$4.5235 | $4.49 | $4.5235 | $5 | $4.41 | 49,640 | 04-18-2024 |
$4.28 | $4.32 | $4.28 | $4.4199 | $4.28 | 10,408 | 04-17-2024 |
$4.28 | $4.55 | $4.28 | $4.7399 | $4.28 | 15,943 | 04-16-2024 |
$4.46 | $4.6 | $4.46 | $4.66 | $4.32 | 20,009 | 04-15-2024 |
$4.6269 | $4.82 | $4.6269 | $4.97 | $4.54 | 18,602 | 04-12-2024 |
$4.77 | $5.06 | $4.77 | $5.1299 | $4.65 | 27,798 | 04-11-2024 |
$5.2 | $5.69 | $5.2 | $5.91 | $4.81 | 31,145 | 04-10-2024 |
$5.23 | $5.09 | $5.23 | $5.2899 | $5.02 | 22,165 | 04-09-2024 |
$5.05 | $5.12 | $5.05 | $5.3399 | $5 | 53,147 | 04-08-2024 |
$5.2 | $4.96 | $5.2 | $5.5 | $4.96 | 39,769 | 04-05-2024 |
$5.3 | $5.29 | $5.3 | $5.31 | $5.05 | 15,757 | 04-04-2024 |
$5.25 | $5.33 | $5.25 | $5.6299 | $5.09 | 46,587 | 04-03-2024 |
$5.45 | $5.7 | $5.45 | $5.7 | $5.18 | 28,686 | 04-02-2024 |
$5.67 | $5.79 | $5.67 | $6.09 | $5.67 | 27,055 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Vir...
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine a...
Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic Properties PR Newswire Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against establi...